Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
2016 · Journal of Cutaneous Pathology · 227 citations
https://doi.org/10.1111/cup.12858
P
Priyadharsini Nagarajan
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
297
Papers
3.8K
Citations
31
h-index
94
i10-index
Priyadharsini Nagarajan is an academic researcher from The University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Nonmelanoma Skin Cancer Studies & Cutaneous Melanoma Detection and Management & Polyomavirus and related diseases. The author has an h-index of 31, co-authored 253 publications.
ORCID: 0000-0002-5346-2669Papers by this author
worksKeratinocyte Carcinomas: Current Concepts and Future Research Priorities
2019 · Clinical Cancer Research · 171 citations
https://doi.org/10.1158/1078-0432.ccr-18-1122
Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients
2018 · Journal for ImmunoTherapy of Cancer · 150 citations
https://doi.org/10.1186/s40425-018-0323-0
Autoimmune dermatologic toxicities from immune checkpoint blockade with anti‐<scp>PD</scp>‐1 antibody therapy: a report on bullous skin eruptions
2016 · Journal of Cutaneous Pathology · 130 citations
https://doi.org/10.1111/cup.12717
Erythema nodosum‐like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy—Report of 2 patients
2017 · Journal of Cutaneous Pathology · 59 citations
https://doi.org/10.1111/cup.13044
Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma
2018 · British Journal of Ophthalmology · 51 citations
https://doi.org/10.1136/bjophthalmol-2018-312277
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat